New York, USA - August 19, 2025 - The recent surge in antifungal drug resistance, as highlighted by both the U.S. FDA's AMR strategic focus and new research in BMC Research Notes on the pressing need for novel antifungal therapies in veterinary medicine, has spotlighted one fact that traditional approaches just won't cut it anymore. Amid this crisis, BioVenic is doubling down on cutting-edge veterinary diagnostics and tailored R&D services to curb the tide.
"It is more than a human health crisis. Drug-resistant fungi and bacteria in veterinary settings are wreaking havoc on livestock, companion animals, and wildlife, threatening food security, animal welfare, and public health. As the BNRC study underscores, the gap between diagnostic capacity and emerging resistant strains continues to grow." Says a scientist at BioVenic. "That's where we come in—providing smart, customizable solutions for antifungal resistance in the veterinary space."
BioVenic's Arsenal: From Rapid Detection to Resistance-Busting Innovations
Leveraging a one-stop platform, BioVenic's vertically integrated services tackle antimicrobial resistance through fungal antimicrobial resistance (AMR) genetics and genomics, phenotypic resistance characterization, pharmacokinetics/pharmacodynamics (PK/PD) studies, and detailed investigations into the mechanisms of antifungal resistance.
It's worth mentioning that their suite of veterinary-focused fungal and bacterial AMR services is designed to help researchers, pharmaceutical companies, and veterinary clinics stay ahead of the resistance curve.
Veterinary Fungal Antimicrobial Resistance (AMR) Solutions
* Veterinary Fungal AMR Genomic Characterization: Employ sequencing technologies like whole genome sequencing, transcriptome analysis, and comparative genomics to study the genetic mutations and mechanisms that confer resistance, thus analyzing the genetic makeup of resistant fungal strains and ultimately pinpointing specific mutations responsible for reduced drug efficacy.
* Veterinary Fungal AMR Phenotypic Characterization: Help understand how genetic changes translate into actual resistance in fungal pathogens by correlating phenotypic data with genetic findings to depict a comprehensive vision of antifungal resistance.
* Veterinary Fungal AMR PK/PD Services: Study the absorption, distribution, metabolism, and excretion of drugs in in vivo, in vitro, and ex vivo models and thereby optimize antifungal dosing regimens.
* Veterinary Fungal AMR Mechanism Studies: By a combination of molecular biology, biochemistry, and microbiology techniques, BioVenic helps uncover the mechanisms underlying antifungal drug resistance, including alterations in drug-target interactions such as mutations that reduce drug affinity and changes that reduce intracellular drug levels such as the upregulation of drug efflux pumps.
Resources for the Veterinary Frontline
In line with its mission to support global animal health efforts, BioVenic has launched a new resource hub, especially for animal infections, offering curated insights into emerging pathogens, AMR trends, and diagnostic innovations. Whether a vet, researcher, or biotech innovator, the resource center is a go-to for the latest in veterinary infectious disease science.
As AMR continues to evolve, so must the tools and strategies used to combat it. Learn more about BioVenic at https://www.biovenic.com.
About
BioVenic's commitment to science-backed, field-ready veterinary solutions is more than just a mission—it's a movement. Because when it comes to fungal resistance, there's no time to sit on the fence.
Media Contact
Company Name: BioVenic
Contact Person: Ashley Hutt
Email: Send Email
Phone: 1-631-593-0561
Country: United States
Website: https://www.biovenic.com